Notwithstanding how long it would take to have a transdermal vaccine on the market- POH will be in the money with a substantive up front as soon as CSL exercise its option with POH. From that point assuming further optmisisation and development by POH we would have milestones to receive. I believe CSL would fastrack such a product as it provides an opportunity to grow their business in many new markets like 3rd world where there is a lack of skilled health care workers; hygene is an issue for safely vaccinating patients ;and cold storage (which is required) is not available for vaccines. Then we have a product that can grow established markets in developed countries. The advantages of delivering vaccines as a non injectable will see greater uptake of flu vaccines by the general populace for example. Mothers of young children worried about side effects from vaccines and the trauma of injecting them- can be reassured by a cleaner non invasive TPM vaccine product with less actives to ensure the protection of their young from incideous childhood diseases.
Reduced side effects, safer administering to patients, and greater efficacy all point to substantive revenue gains and market share for CSL.
thats my take
KC
POH Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)